Boceprevir Study Doubles Hepatitis C Clearance Rate | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Advantage of Longer Treatment After Liver Transplant

Back to News Homepage
Next

All About an HCV-Related Condition: Lichen Planus

Boceprevir Study Doubles Hepatitis C Clearance Rate

The Editors at Hepatitis Central
November 11, 2009

Print this page

Learn about a phase II trial, whereby Boceprevir was added to standard Hepatitis C therapy (pegylated interferon and ribavirin) and was twice as effective at eliminating the Hep C virus compared to standard therapy alone.

Schering hep C drug promising in Phase II study

By Bill Berkrot

NEW YORK, Nov 1 (Reuters) – The addition of Schering-Plough Corp’sSGP.N experimental hepatitis C drug boceprevir after four weeks of treatment with standard medicines led to highly encouraging sustained response rates in a mid-stage study.

The triple combination of boceprevir and the current treatments of pegylated-interferon and ribavirin appeared to knock out the virus at double the rate of the standard drugs alone, according to researchers.

Continue reading the entire article:
http://www.reuters.com/article/rbssHealthcareNews/idUSN3043814620091101

No Comments - be the first!
Share
Share
Previous

Advantage of Longer Treatment After Liver Transplant

Back to News Homepage
Next

All About an HCV-Related Condition: Lichen Planus

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.